Appointment aims to reinforce Bonus Biogroup's leadership at a pivotal moment as the company advances toward Phase 3 clinical trials for its two flagship therapies: BonoFill and MesenCure HAIFA, Israel, July 14, 2025 (GLOBE NEWSWIRE) -- Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stem cells (MSC) to develop novel tissue engineering and cell therapy solutions, announced the appointment of Professor of Cell Therapy and Pediatric Medicin ...